These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review of clinical and laboratory experiences with molindone hydrochloride. Claghorn JL J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):30-3. PubMed ID: 3894340 [TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia associated with molindone treatment. Katz SE Am J Psychiatry; 1990 Jan; 147(1):124-5. PubMed ID: 2293775 [No Abstract] [Full Text] [Related]
7. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Glazer WM; Hafez H Schizophr Res; 1990; 3(5-6):315-20. PubMed ID: 1980827 [TBL] [Abstract][Full Text] [Related]
8. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. Koller W; Curtin J; Fields J Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609 [TBL] [Abstract][Full Text] [Related]
9. [Tardive dyskinesia: an increased risk of neuroleptics in elderly women]. Jessurun AY; Stek ML Tijdschr Gerontol Geriatr; 1995 Oct; 26(5):197-9. PubMed ID: 8750979 [TBL] [Abstract][Full Text] [Related]
11. [The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden]. Povlsen UJ; Noring U; Meidahl B; Korsgaard S; Waehrens J; Gerlach J Ugeskr Laeger; 1987 Jun; 149(25):1682-5. PubMed ID: 3299955 [No Abstract] [Full Text] [Related]
12. [Evaluation of the incidence of tardive dyskinesias in 3 groups of patients treated with different neuroleptics]. Barcia D; Pozo P; Ruiz ME; Forcadell F; Morcillo L; Soria JM; Carrasco E Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1987; 15(1):25-8. PubMed ID: 3577874 [No Abstract] [Full Text] [Related]
13. Dystonic reaction during maintenance antipsychotic therapy. Gardos G Am J Psychiatry; 1981 Jan; 138(1):114-5. PubMed ID: 7446763 [No Abstract] [Full Text] [Related]
14. Basal ganglia iron in tardive dyskinesia: an MRI study. Elkashef AM; Egan MF; Frank JA; Hyde TM; Lewis BK; Wyatt RJ Biol Psychiatry; 1994 Jan; 35(1):16-21. PubMed ID: 8167198 [TBL] [Abstract][Full Text] [Related]
15. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Bishnoi M; Kumar A; Chopra K; Kulkarni SK Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557 [TBL] [Abstract][Full Text] [Related]
16. Analysis of single, double-blind procedures, maintenance of placebo effects, and drug-induced dyskinesia with mentally retarded persons--a brief report [proceedings]. Breuning SE; Ferguson DG; Cullari S Psychopharmacol Bull; 1981 Jan; 17(1):122-3. PubMed ID: 7232641 [No Abstract] [Full Text] [Related]
17. Propranolol-induced tardive dyskinesia in a patient with akathisia. Sandyk R Ann Neurol; 1985 Sep; 18(3):370. PubMed ID: 4051467 [No Abstract] [Full Text] [Related]
18. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]. Branchey MH; Branehey LB; Richardson MA Psychopharmacol Bull; 1981 Jan; 17(1):118-20. PubMed ID: 7232639 [No Abstract] [Full Text] [Related]
19. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Bishnoi M; Chopra K; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768 [TBL] [Abstract][Full Text] [Related]
20. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]